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ABSTRACT
Magnetic resonance-guided focused ultrasound (MRgFUS) is a new emerging neurosurgical 
procedure applied in a wide range of clinical fields. It can generate high-intensity energy 
at the focal zone in deep body areas without requiring incision of soft tissues. Although 
the effectiveness of the focused ultrasound technique had not been recognized because of 
the skull being a main barrier in the transmission of acoustic energy, the development of 
hemispheric distribution of ultrasound transducer phased arrays has solved this issue and 
enabled the performance of true transcranial procedures. Advanced imaging technologies 
such as magnetic resonance thermometry could enhance the safety of MRgFUS. The current 
clinical applications of MRgFUS in neurosurgery involve stereotactic ablative treatments 
for patients with essential tremor, Parkinson's disease, obsessive-compulsive disorder, 
major depressive disorder, or neuropathic pain. Other potential treatment candidates being 
examined in ongoing clinical trials include brain tumors, Alzheimer's disease, and epilepsy, 
based on MRgFUS abilities of thermal ablation and opening the blood-brain barrier. With 
the development of ultrasound technology to overcome the limitations, MRgFUS is gradually 
expanding the therapeutic field for intractable neurological disorders and serving as a trail 
for a promising future in noninvasive and safe neurosurgical care.
Keywords: High-Intensity Focused Ultrasound Ablation; Magnetic Resonance Imaging; 
Ablation; Neurological Disorder; Neurosurgical Procedure
INTRODUCTION
Ultrasound is widely known as a diagnostic or monitoring modality in the medical fields. In 
recent years, however, many investigators have concentrated on the potential role of acoustic 
energy in viable tissues and have been conducting research to investigate its therapeutic use. 
Ultrasound can generate high-intensity energy when focused at focal areas. This focused 
ultrasound (FUS) can produce discrete lesions in deep tissues of the body, even in the 
brain, with minimal effects on tissues near the target point. Since it was first realized that 
ultrasound could be focused when placed on a concave surface of generator in 1935, studies 
on clinical applications of ultrasound have been making a great progress.1 In the 1940s, John 
Lynn and his colleagues were able to create ablative lesions in the bovine liver using intensely-
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focused ultrasound, and they later succeeded in applying similar techniques in animal brain 
tissues.2,3 Fry et al.4,5 first developed a FUS device to produce accurate lesions without 
damaging surrounding tissues. FUS has become more sophisticated with the stereotactic 
surgical technique, and has begun to be applied to clinical practices including psychiatric 
disorders or intractable pain.6,7
Unfortunately, techniques were lacking to overcome the skull issues as a main obstacle 
of ultrasound energy delivery before the 1980s; consequently, opening the cranium was 
inevitable. In the 1990s, however, the accuracy and transmission efficiency of FUS markedly 
improved with the development of imaging techniques and ultrasonic technologies. In 
particular, multiple phased-array techniques of ultrasound transduction enabled the 
realization of non-invasive neurosurgery by transcranial sonication of deep brain tissue.8,9 
Magnetic resonance (MR) thermometry is another key factor enabling the verification of 
the target location and real-time monitoring during the whole treatment procedure using 
FUS.10 These advancements have led FUS to become a promising technique in ablative 
procedures in terms of non-invasiveness and safety. Clinically, FUS has been applied to the 
thermal ablation of body masses, such as uterine fibroids, leiomyomas, other malignancies 
including breast cancers, prostate cancer, and bone metastasis.11-13 Recently, transcranial 
MR-guided FUS (MRgFUS) has been used as a new surgical method applied to various 
neurological disorders, and useful outcomes are increasingly being reported. Thalamotomy 
with MRgFUS for intractable essential tremor (ET) was first approved by the United States 
Food and Drug Administration (FDA) in 2016. Treatments with MRgFUS for Parkinson's 
disease (PD), obsessive-compulsive disorder (OCD), major depressive disorder (MDD), 
and neuropathic pain have obtained international approval in several countries. The 
experimental and clinical applications of FUS are still being investigated. The object of this 
review is to confirm the current status of MRgFUS in neurosurgical field and to search for 
future direction.
PHYSICS OF FOCUSED ULTRASOUND
Ultrasound is a mechanical wave that occurs through a medium and propagates at 
frequencies higher than the range of human hearing of 20 Hz.14 Basically, when ultrasound 
passes through a specific area, reflection and refraction occur at the boundary between 
two media with different acoustic impedances.15,16 Specular reflection, which occurs when 
the acoustic rays contact a relatively smooth surface, usually contributes to delineate the 
interface between two soft tissues; therefore, displaying organ boundaries that could be used 
as diagnostic images.15,17 Another characteristic of ultrasound is attenuation by absorption 
and scattering of acoustic energy. The absorption of acoustic energy into a specific area can 
generate heat energy, leading to protein denaturation and coagulation and cell necrosis, 
and thus resulting in tissue ablation.18-20 Moreover, ultrasound mechanical forces can cause 
formation and oscillation of microbubbles, known as cavitation, and create direct mechanical 
damage to tissue due to its high pressure and shear forces.6,21
Since Gruetzmacher1 first designed a curved quartz plate, which could concentrate 
ultrasound beams at a specific point in 1935, FUS technology has developed markedly. 
In particular, development of phased array transducers with hundreds of piezoelectric 
transducers has led to FUS becoming more efficient in passing through difficult obstacles 
with tissue heterogeneities, such as bone tissue, and effective in focusing multiple points to 
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increase therapeutic volume.9,21,22 Clinicians can modulate the parameters of sonication in 
recent systems, including the intensity of acoustic energy and frequency and sonication time 
depending on the purpose of treatment and characteristics of the subject.
As mentioned above, the thermal and mechanical effects of ultrasound could provide 
the basis for the therapeutic use of ultrasound in clinical fields (Table 1). Stereotactic 
ablative surgery is presently a main clinical application of the MRgFUS procedure, which 
complements the conventional, invasive thermal therapy using radiofrequency (RF) ablation. 
In addition, cavitation effects under specific sonication parameters can open the blood–brain 
barrier (BBB) in a selective and reversible manner. Ultrasound-mediated BBB opening is 
actively explored in the fields of drug delivery into the brain and neuromodulation.23-25
PROCEDURE
Conventionally, clinical MRgFUS lesioning is performed in 3-T MR imaging (MRI) scanners 
using devices such as the Exablate 4000 device (InSightec, Tirat Carmel, Israel) (Fig. 1A). 
This system consists of multiple-phased array transducers with 1,024 ultrasonic elements. 
The entire scalp is completely shaved to prevent scalp burning by absorbed high energy 
from the ultrasound. A stereotactic frame (Cosman−Roberts−Wells stereotactic frame, 
Radionics, Burlington, MA, USA) is then fixed on the patient's head under local anesthesia. 
A flexible silicone membrane with a central hole is applied to the patient's head to seal 
the space between the head and the transducer. This space contains cool, degassed water 
(15°C–20°C) to reduce heating of the scalp. The patient's head on frame are attached to 
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Table 1. Clinical indications and their current state for ablation using MRgFUS
Current state Indications (target)
Approved (by specific countries) ET
Thalamotomy (Vim)
PD
Thalamotomy (Vim)
Obsessive compulsive disorder
Capsulotomy (ALIC)
Neuropathic pain
Thalamotomy (CL)
Ongoing clinical trials PD
Pallidotomy (GP): NCT02003248, NCT02347254, NCT02263885
Subthalamotomy (STN): NCT02912871, NCT02246374
MDD
Capsulotomy (ALIC): NCT03421574, NCT02348411
Brain tumor
Ablation: NCT01473485, NCT00147056, NCT01698437, NCT03028246
BBB opening: NCT02343991
AD
BBB opening: NCT02986932
Epilepsy
Ablation of epileptic foci: NCT02804230
Thalamotomy (AN): NCT03417297
Neuromodulation: NCT02151175
Amyotrophic lateral sclerosis
BBB opening: NCT03321487
MRgFUS = magnetic resonance-guided focused ultrasound, ET = essential tremor, Vim = ventro-intermediate nucleus of thalamus, PD = Parkinson's disease, ALIC 
= anterior limb of internal capsule, CL = centro-lateral nucleus of thalamus, GP = globus pallidus, STN = subthalamic nucleus, MDD = major depressive disorder, 
BBB = blood–brain barrier, AD = Alzheimer's disease, AN = anterior nucleus of thalamus.
the spherical transducer, which again connects with the MRI machine (Fig. 1B). Prior to 
sonication, a series of standard diagnostic MRI scans are obtained to set the target point and 
its stereotactic coordinates. After planning the target, subthreshold, low-power sonication 
is applied several times for 10–20 seconds to reach a peak temperature between 40°C and 
42°C. This process is necessary to confirm the accurate location of the target. It also allows 
practitioners to determine suitable sonication parameters to produce permanent lesions. 
High-power sonication is then delivered to the target area under the guidance of MRI and 
MR thermometry. Acoustic power and energy are steadily increased until target temperatures 
reaching over 54°C. The patient is neurologically evaluated to assess the therapeutic effect 
and side effects during the cooling time right after each sonication. The whole procedure is 
performed without general anesthesia and the patient remains awake and responsive. The 
process of whole procedure is briefly depicted Fig. 2.
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BA
Fig. 1. MRgFUS system for brain surgery. The main device is the Exablate 4000 device (InSightec, Tirat Carmel, 
Israel) in combination with 3-T MRI scanner (A). The head of the patient is fixed to a stereotactic frame and 
assembled with a MRI machine (B). 
MRgFUS = magnetic resonance-guided focused ultrasound, MRI = MR imaging.
Patient assessment on-tableFrame fixation and patient preparation
Image registration
Treatment planning
Closed loop feedback
Fig. 2. Flow chart of procedure using MRgFUS ablation. 
MRgFUS = magnetic resonance-guided focused ultrasound.
CLINICAL APPLICATIONS
ET
ET is one of the most common movement disorders, involving involuntary, rhythmic shaking 
affecting mostly the hands, and sometimes the head or other part of the body. Its prevalence 
is approximately 4% and half of patients with ET require surgical treatment due to medically-
refractory state.26 Surgical treatment options involve RF ablation or deep brain stimulation 
(DBS), mainly targeting to the ventral intermediate (Vim) nucleus of the thalamus or 
posterior subthalamic area (Fig. 3A). These areas reportedly belong to the motor circuitry, 
which connects the cerebellum and cortex, and is historically associated with tremors.27,28 
Since several pilot studies have shown the potential efficacy and safety of this new surgical 
approach for ET, the clinical outcomes of MRgFUS thalamotomy have been accumulating. 
Patients treated in this manner commonly present with favorable reduction in tremor 
scores after treatment in the early phase and much improved functions of daily living or 
quality of life.29-31 Reported side effects included dizziness, nausea or vomiting, ataxia, and 
paresthesia, but no fatalities have been reported.29-31 In 2016, a randomized, multicenter trial 
showed that hand tremor scores improved from 18.1 points at baseline to 9.6 at 3 months 
in a MRgFUS thalamotomy group compared with a sham group.32 They also found that the 
treatment effect was maintained at 12 months with an acceptable rate of side effects. These 
achievements validated the effectiveness and safety of MRgFUS thalamotomy and led to the 
procedure obtaining official approval, and to date, ET is the only FDA-approved neurological 
indication for transcranial MRgFUS ablation. Recently, a meta-analysis reported favorable 
outcome after MRgFUS lesioning for ET. The percentage improvements in the Clinical Rating 
Scale for Tremor (CRST) were 62.2%, 62.4%, and 69.1% for CRST total, part A, and part C, 
respectively.33 The Quality of Life in Essential Tremor score was also improved by 46.5%.33 
In addition, long-term effectiveness was evaluated in a prospective study, which showed 
that the tremor and disability scores were sustained at the 2-year follow up.34 This treatment 
combines more advanced imaging technology, such as tractography, and confirms the 
possibility of continuous development toward better accuracy and safety.35,36
5/16https://jkms.org https://doi.org/10.3346/jkms.2018.33.e279
Future of Neurosurgery with Magnetic Resonance-Guided Focused Ultrasound
B CA
Fig. 3. Brain magnetic resonance images after the ablation procedure using MRgFUS. Well-defined small lesions are identified (white arrows) on T2 weighted 
imaging after unilateral thalamotomy for ET (A), unilateral pallidotomy for PD (B), bilateral capsulotomy for psychological disease (C). 
MRgFUS = magnetic resonance-guided focused ultrasound, ET = essential tremor, PD = Parkinson's disease.
PD
PD is a complex movement disorder, involving the clinical trial of akinesia/bradykinesia, 
resting tremors, and muscular rigidity. PD is deeply related to the disruption of the 
motor circuitry because the symptoms of PD result from progressive loss of innervation 
of dopaminergic neurons in the motor area of the basal ganglia. Conventional surgical 
treatments of PD have targeted specific areas of the motor circuit associated with the 
patient's main symptoms. Common targets for both DBS and lesioning procedures include 
the subthalamic nucleus, globus pallidus interna (GPi), and Vim among others.37-39 These 
areas are also being explored as potential targets for MRgFUS procedures for PD.
Magara et al.40 demonstrated the feasibility and safety of the MRgFUS pallidothalamic 
tractotomy (PTT) for patients with medically-resistant PD. They applied repetitive sonication 
to 9 of 13 included patients, achieving final temperatures for appropriate lesions. These 
nine patients experienced a mean reduction of 60.9% in the Unified Parkinson's Disease 
Rating Scale (UPDRS) score and 56.7% improvement in global symptom relief at the 3 
months follow-up after MRgFUS PTT.40 Tremor-dominant PD is a good indication of 
MRgFUS thalamotomy, which has been validated in several clinical trials.41 Bond et al.41 
showed differences in clinical outcome between patients with PD who underwent unilateral 
MRgFUS thalamotomy and a sham procedure. They found that the median tremor scores 
of 20 patients improved by 62% from baseline and the median UPDRS motor scores of the 
on-medication state also improved by 8 points from baseline after MRgFUS thalamotomy, 
which was much better than the outcome of the sham procedure.41 Recently, the preliminary 
efficacy of unilateral subthalamotomy using MRgFUS was reported by an open-label pilot 
study, which found that the mean UPDRS part III scores in the treated hemibody improved by 
53% from baseline to 6 months in the off-medication state and by 47% in the on-medication 
state.42 The GPi is another important functional target for surgical treatment in patients 
with PD, mainly targeting dyskinesia (Fig. 3B). Clinical studies exploring the feasibility and 
safety of unilateral MRgFUS pallidotomy for Parkinsonian dyskinesia are ongoing. The 1-year 
follow-up results of a study conducted by our group (NCT02003248) have been recently 
accepted and will shortly be published.
Although it is at the experimental stage, the possibility of drug or gene delivery using BBB 
opening by FUS is also being continuously studied.43-45 This potential of MRgFUS raises 
expectations for future treatments for intractable neurodegenerative disorders.
Neuropsychological disorders
OCD, Tourette syndrome, and MDD are traditional neurosurgical indications that have 
been previously treated via lesioning procedures or DBS. These disorders reportedly result 
from abnormal neural circuits involving limbic areas. There are various targets for ablation, 
including the anterior limb of the internal capsule (Fig. 3C), anterior cingulate cortex, 
subgenual cingulate cortex, and ventral striatum.46-48 Firstly, Jung et al.49 attempted to 
perform bilateral capsulotomy via MRgFUS in patients with medically-refractory OCD 
and they reported a marked improvement over the 6 months follow-up in the Yale-Brown 
Obsessive-Compulsive Scale (YBOCS) of 33%. They also identified immediate and sustained 
improvements in the Hamilton Depression Rating Scale (HAM-D) with a mean reduction 
of 61.1% and the Hamilton Anxiety Rating Scale (HAM-A) with a mean reduction of 69.4%. 
The treatment-related adverse events were minimal.49 The long-term outcome over 2 years 
in the same group reaffirmed the efficacy of MRgFUS capsulotomy to manage obsessive, 
compulsive, depressive, and anxiety symptoms in patients with OCD.50 The scores of the 
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YBOCS, HAM-D, and HAM-A decreased significantly across the 2-year follow-up period 
and the functioning scores improved without neuropsychological changes.50 Bilateral 
capsulotomy using MRgFUS has been applied to MDD based on the improvement of 
depression scores in previous OCD results. Kim et al.51 first reported a case of a 56-year-
old woman with MDD who underwent MRgFUS capsulotomy, resulting in considerably 
decreased scores in the HAM-D, and Beck's Depression Inventory Scores from baseline to the 
1-year follow-up. A clinical trial on bilateral anterior capsulotomy for MDD has recently been 
completed and the results are pending announcement. Regarding neuromodulation, FUS-
induced BBB opening may increase brain-derived neurotrophic factor levels, drug delivery, 
and hippocampal neurogenesis that can result in new modes of anti-depressive treatment.52
Chronic pain
Chronic neuropathic pain poses a challenge for modern medicine. It is difficult to manage 
with simple approaches because of numerous different symptomatic presentations, various 
affecting areas, and heterogenous mechanisms. Although the medical treatments including 
sodium-channel blockers and anticonvulsants are the mainstay for alleviating chronic pain, 
interventional nerve blocks and physical therapy could be useful to reduce severe pain.53,54 
Further, surgical treatments can be applied and specific options are selected based on the 
body area and cause of pain, including the cortex, cingulum, thalamus, spinal cord, and 
spinal nerves. In particular, the medial thalamus has been targeted by a variety of surgical 
modalities as the main relay station of the somatosensory pathway. Medial thalamotomy via 
RF ablation or radiosurgery and thalamic DBS have proven their effectiveness of pain control 
in patients with intractable pain.55-57 Jeanmonod et al.58 demonstrated that patients with 
chronic neuropathic pain experienced a mean pain relief of 49% at the 3-months follow up 
and 57% at the 1-year follow up after central lateral thalamotomy via non-invasive treatment 
using MRgFUS. They have tried MRgFUS ablation in heterogenous pain patterns and causes 
from brain lesions to spinal cord injury or peripheral nerve problems.58 Some countries have 
been officially approved MRgFUS ablation for chronic pain, and the United States is currently 
recruiting participants with uncontrolled chronic pain who are willing to undergo MRgFUS 
ablation in a phase I clinical trial (NCT03111277). Large-scaled clinical outcomes of MRgFUS 
thalamotomy for pain will be available in the near future.
Brain tumors and drug delivery
The therapeutic abilities of MRgFUS confined to focal regions have led to a breakthrough 
in the treatment of brain tumors because MRgFUS can limit treatment-related toxicity to 
normal brain tissue. Brain tumor management using MRgFUS techniques is classified 
into two different ways. One is the thermal ablation effect on tumor tissue using focused 
ultrasonic energy and the other is the ability to open the tight junctions of the BBB and to 
deliver the therapeutic agent more effectively to the target brain region.
MRgFUS enables the eradication of target cells noninvasively and safely with minimal 
injury to the adjacent normal area. Although resection is the main treatment for brain 
tumors for the purposes of histopathologic confirmation and cytoreduction, some cases 
are ineligible for open surgery. Currently, the standard option for surgically inaccessible 
lesions is radiosurgery or radiotherapy. These therapies have risks of complications, such as 
radiation necrosis or leukoencephalopathy due to radiation toxicity to viable tissue.59,60 Laser 
interstitial thermotherapy (LiTT) is one of the emerging options for tumor ablation and its 
effects have been shown in patients with recurrent glioblastoma and metastatic brain tumors, 
but its complication rate is still relatively high and it is an unsuitable option in cases with 
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nearby great vessels or hemorrhage.61,62 To date, several studies have reported successful 
cases of applying MRgFUS to achieve tumor ablation in a small number of patients with 
glioblastoma.20,63 A clinical trial using MRgFUS to target brain tumors (NCT01473485) has 
recently been completed and the results will be available soon. As is already clinically used 
as an available treatments, either primary or palliative, for body cancers, MRgFUS should be 
accompanied by studies that will determine the survival benefit and ways of improving the 
technical efficiency of using ultrasonic energy.
Historically, the goal of chemotherapy for brain tumors was to deliver the most effective 
agents to tumor cells passing through the BBB. Many attempts have made to enhance 
the efficiency of drug delivery, including receptor modifying nanoparticles, intranasal 
injections, and chemo-agent wafers (Bis-chloroetheylnitrosourea wafers).64-66 However, 
all these methods carry risks of iatrogenic damage and significant toxicity by the drugs 
to normal brain tissues. BBB opening using MRgFUS has advantages over the existing 
methods. MRgFUS can disrupt the tight junctions of the BBB transiently for up to 24 hours 
by oscillation of microbubbles, known as stable cavitation, then it can restore the BBB to its 
previous state.67-70 When the range of sonication is defined under MRI guidance, MRgFUS 
can accurately increase the drug concentration within a specific volume of brain tumor 
while preserving normal brain tissues or other systemic organs.70,71 In animal experiments, 
the intravenous methotrexate concentration in the brain of healthy rabbits was 13 times 
higher with MRgFUS than without MRgFUS.72 In glioma rabbit models, the doxorubicin 
concentration was 14 times higher after 24 hours when MRgFUS-induced BBB opening was 
added.73 Improved drug delivery using MRgFUS also has benefits for increasing median 
survival time over no treatment.64 Regardless of these promising results from preclinical 
studies, clinical trials on human brain tumors remained to be conducted. The only relevant 
study in humans is a phase I clinical trial, which used MRgFUS to open the BBB in the frontal 
cortex in patients with Alzheimer's disease (AD) (NCT02986932). The results are yet to be 
reported. Another clinical trial on BBB opening in human glioblastoma is in the process of 
preparation and will be recruit patients with glioblastoma this year.
Other emerging indications
In addition to the previously mentioned diseases, there are many applicable disease entities 
and they are being tried in real clinical practice based on the satisfactory results of basic 
experiments.
Stroke is one of the most significant causes of long-term morbidity and mortality 
worldwide.74,75 Large-vessel occlusion is the main cause of acute ischemic stroke and is 
typically treated with endovascular mechanical thrombectomy or thrombolytic agents76-78; 
some patients are eligible for more invasive open surgeries, such as craniotomy or 
decompressive craniectomy.79,80 The concept of sonothrombolysis using MRgFUS has 
been applied as an alternative or neoadjuvant therapy for patients with stroke who cannot 
benefit from conventional therapies. This therapy is performed based on the piezoelectric 
effect, which generates acoustic waves to induce inertial cavitation, consequently leading 
to clot disintegration.81-85 Several in vitro models have attempted to determine the optimal 
sonication parameters for effective thrombolysis and minimal injury to adjacent structures 
and they achieved a 58%–95% of recanalization rate using animal clots and a 10%–42% of 
thrombolysis rate using human clots under conditions of pulsed sonication.86-88 In addition, 
Harnof et al.89 and Monteith et al.90 reported clot liquefaction achieved with/without 
temperature increase in surrounding tissues in in-vivo experiments.
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Epilepsy is another potential field of MRgFUS surgery application. Approximately 20%–40% 
of patients with epilepsy do not respond to antiepileptic drugs and they need surgical 
interventions. Except for neuromodulation, the most frequently employed surgical options 
for epilepsy are lobectomy or focal lesionectomy, which require invasive procedures. 
Numerous studies have explored minimal invasive approaches, such as stereotactic 
radiosurgery or LiTT. However, stereotactic radiosurgery has hazards related to ionizing 
radiation and the long latency of the therapeutic effect, and LiTT cannot be performed 
without scalp incision or trephination.91-94 MRgFUS ablation can provide more noninvasive 
tissue destruction using high ultrasonic energy through the intact skull. Now, a phase I 
clinical trial (NCT02804230) is underway to determine the feasibility and safety of MRgFUS 
ablation for epilepsy related to subcortical, visible pathologies including hypothalamic 
hamartomas and tuberous sclerosis. Apart from its ablation effects, MRgFUS can be 
utilized to decrease cortical excitability and suppress epileptogenic discharges because 
the mechanical effects of acoustic waves can change the cellular membrane properties. A 
trial aiming to investigate the neuromodulatory effect of low-frequency FUS is ongoing 
(NCT02151175).
DISCUSSION
MRgFUS is undoubtedly an effective treatment modality; however, there are still limitations 
to overcome. First, the need to penetrate the skull is a main barrier to the energy transfer 
efficiency of MRgFUS. Ultrasound has its own characteristics of reflection and refraction 
that occur at the boundary between two media with different acoustic impedances.17,95 The 
human skull is a complex medium composed of heterogenous and viscoelastic structures. 
In the process of ultrasound transmission through the skull, there is unwanted energy loss 
and attenuation. Actually, several studies have shown that some of the included cases failed 
to achieve lesioning via MRgFUS because sufficient temperature rise was not obtained. 
Elias et al.32 found that 5 of 76 patients did not achieve sufficient energy delivery during 
MRgFUS thalamotomy for their ET. Chang et al.30 also reported three of 11 patients where 
lesioning failed due to insufficient temperature into the thalamic target for ET management. 
Jeanmonod et al.58 reported that they succeeded in delivering ultrasonic energy through the 
skull only 9 of 11 patients with medication-intractable neuropathic pain. The skull density 
ratio (SDR), i.e., the ratio of the Hounsfield unit value on brain computed tomography 
between the marrow layer and cortical layer is a known important factor because higher SDR 
(> 0.45) could be associated with lower energy requirement for generating temperature rise 
at the target tissue.96 Yet, there is no formal cut off value of SDR for the MRgFUS procedure; 
further studies are needed to explore the valid reference value to select suitable patients. 
In addition, each sonication transducer in the spherical helmet has an incident angle when 
ultrasound beams heat the skull, and then part of them is refracted due to non-spherical 
skull calvaria. This possibly obstructs penetration of ultrasonic energy especially in cases of 
superficial targets or more lateral targets.97-99
Another clinical obstacle is that MRgFUS is usually performed with only empirical 
parameters of sonication. In terms of frequency of sonication, high-frequency, over 650 
kHz, has the advantages of accurate focusing and consequent safety, but is more rapidly 
attenuated by the skull than low-frequency ultrasound.86,100 On the contrary, low-frequency 
ultrasound has less energy attenuation, but also less focusing ability, resulting in potential 
risk of damaging surrounding tissues.86,100-102 Although the MRgFUS technique is still 
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evolving, more efforts are required to understand the basic principles of ultrasound and to 
increase the efficiency of the current technology, as well as to expand the clinical indications 
of application of this novel treatment.
MRgFUS is an important first step for the ideal neurosurgery for neurological disorders 
due to its noninvasive nature and safety. Moreover, this new approach has potential beyond 
ablation and could be applied to a wide range of clinical fields, including brain tumor, AD, 
epilepsy, stroke, etc. Although there are still technical limitations, MRgFUS is expected to 
become a new future in neurosurgical treatment because numerous clinical and preclinical 
studies have shown the feasibility of MRgFUS and several studies are still ongoing. In the 
near future, if larger scaled data including from phase II and III trials are confirmatory of 
its efficacy, MRgFUS can open a new chapter in breakthrough treatments for intractable 
neurological diseases.
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